Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma

American Journal of Clinical Pathology

Volumn 143, Issue 2, 2015, Pages 257-264

  Koopman, Timco ^a   Louwen, Maarten ^a   Hage, Mariska ^a   Smits, Maria M ^a   Imholz, Alex L T ^a  

^a DEVENTER HOSPITAL   (Netherlands)

Author keywords

Esophageal cancer; Gastric cancer; Gastroesophageal cancer; Human epidermal growth factor 2 (HER2); Immunohistochemistry (IHC)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL FEATURE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATHOLOGIST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; VALIDITY; ADENOCARCINOMA; BIOSYNTHESIS; ESOPHAGUS TUMOR; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; OBSERVER VARIATION; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925283868     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPCX69HGDDGYCQ     Document Type: Article

References (34)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. American Cancer Society. Global Cancer Facts and Figures. 2nd ed. Atlanta, GA: American Cancer Society; 2011.
3. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27-39.
4. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151-159.
5. Kamangar F, Dores GM, Anderson WF, et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
6. Horner MJ, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975-2009. 2012. http://seer.cancer.gov/csr/1975-2009/. Accessed August 1, 2013.
7. Chau I, Norman AR, Cunningham D, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol. 2009;20:855-891.
8. Chua TC, Merrett ND. Clinicopathological factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer. 2012;130:2845-2856.
9. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol. 2006;24:2903-2909.
10. Santini D, Vincenzi B, Pantano F, et al. "All action no talk": the role of HER2/neu in adjuvant therapy choice for gastric cancer. Ann Oncol. 2013;24:1715-1717.
11. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
12. Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761.
13. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol. 2012;23:2656-2662.
14. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
15. Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathological features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012;18:546-554.
16. Bang Y, H. Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27:15s.
17. Reichelt U, Duesedau P, Tsourlakis MC, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120-129.
18. Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol. 2011;24:899-907.
19. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
20. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307.
21. Gancberg D, Jarvinen T, Di Leo A, et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat. 2002;74:113-120.
22. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982.
23. Fox SB, Kumarasinghe MP, Armes JE, et al. Gastric HER2 testing study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol. 2012;36:577-582.
24. Warneke VS, Behrens HM, Böger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013;24:725-733.
25. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
26. Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637-650.
27. HER2 testing: gastric cancer. her2testing.org. Basel Switzerland: F. Hoffmann-La Roche; 2013. Accessed December 15, 2013.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
29. Sawa J, Morikawa T. Interrater reliability for multiple raters in clinical trials of ordinal scale. Drug Inform J. 2007;41:595-605.
30. Heidl G, Langhans P, Mellin W, et al. Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol. 1993;120:95-99.
31. Conger AJ. Integration and generalization of kappa for multiple raters. Psychol Bull. 1980;88:322-328.
32. Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer. 2000;89:1418-1424.
33. Yamashita K, Sakuramoto S, Katada N, et al. Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer. Hepatogastroenterology. 2009;56:276-281.
34. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.